Adding AKT Inhibitor Shows Benefit in PTEN-Deficient Prostate Cancer

(MedPage Today) -- The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone...
Source
MedPage Today
Opens original article in a new tab



